ptk787

Glucagonoma

Mayo ClinicPhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

1 Active assets in the Glucagonoma cohort.

Asset / Sponsor	Phase	Rating
Capecitabine Vanderbilt-Ingram Cancer Center	Phase 2	BB
Everolimus Emory University	Phase 2	B
gw786034 National Cancer Institute (NCI)	Phase 2	B
Regorafenib University of Southern California	Phase 2	B
Temsirolimus National Cancer Institute (NCI)	Phase 2	B

View all 15 →

Same molecule, other indications

ptk787 is also rated in:

neoplasmDormant

BB

Indicative ·

64 / 100

rectal neoplasmDormant

B

Indicative ·

60 / 100

colonic neoplasmDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.